Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors

NCT07170293 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Solid Cancers

Interventions

DRUG: Tunlametinib

Sponsor

Tianjin Medical University Second Hospital